Jacky Luiten

110 | Chapter 7 References 1. van Luijt PA, Heijnsdijk EA, Fracheboud J et al: The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. Breast Cancer Res 2016;18(1):47. 2. Henrot P, Leroux A, Barlier C et al: Breast microcalcifications: the lesions in anatomical pathology. Diagn Interv Imaging 2014;95(2):141 ‐ 152. 3. Jing H. YY, Wernick M.N., Yarusso L.M., Nishikawa R.M.: A comparison study of image features between FFDM and film mammogram images. Med Phys 2012;39(7):4386 ‐ 4394. 4. Bleyer A, Welch HG: Effect of three decades of screening mammography on breast ‐ cancer incidence. N Engl J Med 2012;367(21):1998 ‐ 2005. 5. Hollingsworth A: Overestimating Overdiagnosis in Breast Cancer Screening. Cureus 2017; 9(1):e966. 6. de Gelder R: Predicting the Benefits and Harms of Breast Cancer Screening: Current debates and future directions. Ph.D. thesis. Erasmus MC: University Medical Center Rotterdam; 2012. 7. Seigneurin A, Labarere J, Francois O et al: Overdiagnosis and overtreatment associated with breast cancer mammography screening: A simulation study with calibration to population ‐ based data. Breast (Edinburgh, Scotland) 2016;28:60 ‐ 66. 8. Duffy SW, Agbaje O, Tabar L et al: Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res 2005;7(6):258 ‐ 265. 9. NABON. Feder atie Medisch Specialisten ‐ Richtlijn mammacarcinoom Last up dated 01 ‐ 07 ‐ 2018. Available from: https://richtlijnendatabase.nl/richtlijn/borstkanker/dcis.html. 10. Cardoso F, Kyr iakides S, Ohno S et al: Early breast cancer: ESMO Clinical Pra ctice Guidelines for diagnosis, treat ment and follow ‐ up. Ann Oncol 2019;30(10):1674. 11. Donker M, Litiere S, Werutsky G et al: Breast ‐ conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15 ‐ year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 2013;31(32):4054 ‐ 4059. 12. Warnberg F, Garmo H, Emdin S et al: Effect of radiotherapy after breast ‐ conserving surgery for ductal carcinoma in situ: 20 years follow ‐ up in the randomized SweDCIS Trial. J Clin Oncol 2014; 32(32):3613 ‐ 3618. 13. Holmberg L, Garmo H, Granstrand B et al: Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol 2008;26(8):1247 ‐ 1252. 14. Elshof LE, Schaapveld M, Schmidt MK et al: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population ‐ based cohort of 10,090 women. Breast Cancer Res Treat 2016;159(3):553 ‐ 563. 15. Meretoja TJ, Heikkila PS, Salmenkivi K, Leidenius MH. Outcome of patients with ductal carcinoma in situ and sentinel node biopsy. Ann Surg Oncol 2012;19(7):2345 ‐ 2351. 16. Lyman GH, Somerfield MR, Bosserman LD et al: Sentinel Lymph Node Biopsy for Patients With Early ‐ Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;35 (5):561 ‐ 564. 17. IKNL. Netherlands Ca ncer Registry Available from: https ://www.iknl.nl/en/ncr. 18. PALGA Foundation [https://www.palga.nl/en/about ‐ stichting ‐ palga/stichting ‐ palga.html] 19. van Steenbergen L N, Voogd AC, Roukema JA et al: Time trends and inter ‐ hospital variation in treatment and axill ary staging of patients with ducta l carcinoma in situ of the breast in the era of screening in Southern Netherlands. Breast (Edinburgh, Scotland) 2014;23(1):63 ‐ 68. 20. Rakovitch E, Pignol JP, Chartier C et al: The management of ductal carcinoma in situ of the breast: a screened population ‐ based analysis. Breast Cancer Res Treat 2007;101(3):335 ‐ 347. 21. van Dongen JA, Voogd AC, Fentiman IS et al: Long ‐ term results of a randomized trial comparing breast ‐ conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000;92(14):1143 ‐ 1150.